The severe bone loss that occurred in the anti-RANKL antibody discontinuation mouse model reproduced the specificity of discontinuing RANKL-targeting treatment, and was similar to the phenomenon observed in patients with osteoporosis who discontinue treatment. This evidence concerns the gene TNFSF11 and osteoporosis.